Get the app
US › Healthcare

Larimar Therapeutics Inc (LRMR)

US · Healthcare · Biotechnology

$1.99-0.25%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$-32.8M
EPS
$-0.30
EPS estimate
$-0.39

EPS came in at -0.30 against a street estimate of -0.39 — a beat of 23.1%.

Key statistics

Market cap
$262.8M
Forward P/E
0.0
P/B
3.15
Book value
$1.22
EPS (TTM)
$-1.99
52-week high
$6.42
52-week low
$2.13
50-day MA
$3.74
200-day MA
$3.90
Beta
0.69

Analyst view

Analysts rate Larimar Therapeutics Inc a strong buy (11 buy, 0 hold, 0 sell out of 11) with an average price target of $14.40.

Shareholding

Insiders
1.19%
Institutions
93.42%

Largest institutional holders

FundStake
Deerfield Management Co34.28%
Blue Owl Capital Holdings LP8.82%
BlackRock Inc5.47%
Defilade Capital Management, L.P.3.53%
Driehaus Capital Management LLC3.05%
Vanguard Capital Management, LLC2.86%
RTW INVESTMENTS, LLC2.47%
AQR Capital Management LLC2.28%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Larimar Therapeutics Inc — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-19.